Federated Hermes, Inc. and four affiliated reporting persons filed Amendment No. 13 to their beneficial ownership statement with respect to aTyr Pharma Inc. common stock on November 4, 2026, disclosing a combined beneficial ownership position of zero shares as of October 31, 2026.

Key Highlights

  • Five reporting persons: Federated Hermes, Inc., Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue each reported 0.00 shares beneficially owned.
  • Zero ownership across all categories: Sole voting power, shared voting power, sole dispositive power, and shared dispositive power were each reported as 0.00 for every reporting person.
  • Percent of class: Each reporting person reported 0% of the class of common stock held as of the event date of October 31, 2026.
  • Amendment number: This is Amendment No. 13, indicating a series of prior filings by the same reporting group regarding aTyr Pharma common stock (CUSIP 002120202).
  • Triggering event: The date of the event requiring this filing is stated as October 31, 2026.
  • Ordinary course certification: The filing certifies that any securities previously held "were acquired and are held in the ordinary course of business" and not to influence control of the issuer.

Federated Hermes Group Discloses Full Exit from aTyr Pharma Common Stock

According to the filing, Federated Hermes, Inc., a Pennsylvania-based holding company, together with the Voting Shares Irrevocable Trust and three individual signatories - Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue - collectively reported zero beneficial ownership of aTyr Pharma Inc. common stock. aTyr Pharma, a clinical-stage biopharmaceutical company headquartered at 10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121, is focused on the discovery and development of medicines based on tRNA synthetase biology. The common stock subject to this filing carries CUSIP number 002120202.

The filing identifies Federated Hermes, Inc. as a parent holding company (type "HC") organized in Pennsylvania, while Voting Shares Irrevocable Trust is classified as type "OO" and the three individual Donahue family members are each classified as type "IN." All five cover pages in the filing show identical figures: 0.00 for sole voting power, 0.00 for shared voting power, 0.00 for sole dispositive power, and 0.00 for shared dispositive power, with an aggregate beneficial ownership of 0.00 shares representing 0% of the class.

The filing states that Item 5 applies, indicating "ownership of 5 percent or less of a class," and that Item 6, regarding ownership of more than 5 percent on behalf of another person, is "Not Applicable." Three exhibits are referenced: Exhibit 1 addresses the Item 3 classification of reporting persons, Exhibit 2 is an agreement for joint filing, and Exhibit 3 is a power of attorney. J. Christopher Donahue signed on behalf of Federated Hermes, Inc. as its President, and both Thomas R. Donahue and Ann C. Donahue signed as trustees of the Voting Shares Irrevocable Trust.

What Was Disclosed

Federated Hermes, Inc. and four affiliated persons filed Amendment No. 13 disclosing zero beneficial ownership of aTyr Pharma Inc. common stock as of October 31, 2026, with 0% of the class held across all voting and dispositive power categories.